New global survey demonstrates an increasing demand for new treatments for non-Hodgkin's Lymphoma

December 10, 2001

10 December 2001, 43rd Annual Meeting of the American Society of Hematology, Orlando, US - In a survey of 230 physicians from around the world, the majority interviewed (63%) have seen an increase in the last five years in the number of patients suffering from non-Hodgkin's lymphoma (NHL). The average reported increase in cases of NHL, a form of cancer of the immune system, was 13%.

The survey also showed that 9 out of 10 physicians (91%) who prescribe MabThera® (rituximab) for the treatment of this increasingly common form of cancer, said there is a significant improvement in their patients' quality of life.

The survey found that physicians are increasingly prescribing MabThera for the treatment of NHL. Of those who have prescribed MabThera, 92% said their usage increased over the last three years and, of these, over half (62%) said their increased prescribing of MabThera in combination with chemotherapy is based on proven efficacy. This reflects clinical studies that have demonstrated that MabThera can increase survival when combined with conventional chemotherapy without additional toxicity, or compromising tolerability.1

Approximately 1.5 million people around the world are affected by NHL, which is the third fastest growing form of cancer after skin melanoma and lung cancer.2

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address needs for the prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life.

Roche is a world leader in oncology. Its franchise includes three drugs with survival benefit: MabThera (non-Hodgkin's lymphoma), Xeloda (colorectal cancer, breast cancer), and Herceptin (breast cancer), It also includes NeoRecormon (anaemia in various cancer settings), Roferon-A (leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma), Neupogen (neutropenia) and Kytril (chemotherapy and radiotherapy-induced nausea).
-end-
Roche Oncology has four research sites (two in the US, Germany and Japan) and four HQ Development sites (two in the US, UK and Switzerland).

The survey was conducted by The Ketchum Research and Measurement Department on behalf of Roche.

References:

1. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276

2. World Health Report 2000, World Health Organization, www.who.int

Notes to Editors:

1. Lymphomas generally are classified into two equal groups: one half are indolent (low grade) lymphomas while the remaining are aggressive (intermediate/high grade). Intermediate/high grade lymphomas spread rapidly, and left untreated, can be fatal within six months to two years.

2. MabThera was co-developed by Roche, Genentech and IDEC Pharmaceuticals. It was first approved by the U.S. Food and Drug Administration (FDA) in November 1997 and is marketed in the US under the trade name Rituxan by Genentech and IDEC. MabThera received European approval (for relapsed or chemoresistant low grade (indolent) or follicular non-Hodgkin's lymphoma.) in June 1998. MabThera is a monoclonal antibody that works by binding to a particular protein (the CD20 antigen) on the surface of normal and malignant B-cells. It then recruits the body's natural defences to attack and kill the marked B-cells. Stem cells present in the bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months

3. In October 2001 European health authorities gave a positive opinion recommending MabThera be approved for the treatment of aggressive NHL. The EU authorities are expected to announce their decision in early 2002.

For further information please contact:

Carrie Deverell Rina Amin Roche Ketchum Tel: +41 61 688 9848 Tel: +44 20 7611 3513 Mobile: +41 795 069 940

Ketchum UK

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.